{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:43:41Z","timestamp":1777927421983,"version":"3.51.4"},"reference-count":35,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Khon Kaen University Faculty of Medicine","award":["(Grant Number 64304)."],"award-info":[{"award-number":["(Grant Number 64304)."]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A ritonavir-boosted protease inhibitor (PI)-based antiretroviral therapy (ART) regimen can cause abnormal lipid levels and increased incidence of cardiovascular disease. Switching to a dolutegravir (DTG)-based regimen has been shown to improve blood lipid levels, but data in the Thai population are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A prospective cohort study was conducted at Srinagarind Hospital between April 28, 2021, and April 30, 2022. Patients were eligible if they (1) were over 18\u00a0years of age, 2) had received a ritonavir-boosted PI-based regimen for at least three months, and 3) had documented plasma HIV RNA levels below 50\u00a0copies\/mL within six months before the enrollment. All eligible patients included in the study switched from a ritonavir-boosted PI-based ART regimen to a DTG-based regimen. The primary outcome was changes in low-density lipoprotein cholesterol (LDL-C) levels from baseline to week 24.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty-six eligible patients were enrolled, 71.7% of whom were male, with a mean age of 49.4\u00a0years. Mean body weight was 62.7\u00a0kg and body mass index (BMI) was 22.86\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . The majority of patients had been on a regimen of boosted atazanavir (ATV\/r; 60.9%), followed by boosted lopinavir (LPV\/r; 37.0%). Six patients were withdrawn from the study. At week 24 after switching to DTG, LDL-C was significantly lower than at baseline, with a difference of \u221215.1\u00a0mg\/dL (95% confidence interval [CI; \u221223.3 to \u22126.8]; p-value &lt; 0.001), as were total cholesterol and triglycerides, with differences of \u221222.1\u00a0mg\/dL (95% CI [\u221233.3 to \u221210.8]; p-value &lt;0.001) and \u221267.7\u00a0mg\/dL, (95% CI [\u221288.3 to \u221247.0]; p-value 0.001), respectively. There were no significant changes in body weight (0.51\u00a0kg; 95% CI [\u22120.37 to 1.38]; p-value 0.251) or BMI (0.17\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ; 95% CI [\u22120.14 to 0.48]; p-value 0.284) from baseline to week 24. In addition, 39 of 40 patients (97.5%) maintained virological suppression (HIV RNA &lt;50\u00a0copies\/mL), with only one patient (2.5%) developing virological failure. Three grade 3 adverse events were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Switching from a boosted PI-based ART regimen to a DTG-based regimen in people living with HIV\/AIDS who had attained prior virological suppression resulted in a significant reduction in total cholesterol, LDL-C, and triglyceride levels, but did not increase the patient\u2019s body weight at 24\u00a0weeks of follow-up. Furthermore, the DTG-based regimen was also highly effective in maintaining virological suppression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>Thai Clinical Trials Registry, TCTR20210625004.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09564624221137972","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T09:25:45Z","timestamp":1668504345000},"page":"98-107","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Virological outcomes and metabolic effects after switching from ritonavir-boosted protease inhibitors to a dolutegravir-based regimen in virologically suppressed patients living with HIV"],"prefix":"10.1177","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0400-2092","authenticated-orcid":false,"given":"Wantin","family":"Sribenjalux","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand"},{"name":"Research and Diagnostic Center for Emerging Infectious Diseases (RCEID), Khon Kaen University, Khon Kaen, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tharatorn","family":"Nuntawit","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3184-9229","authenticated-orcid":false,"given":"Atibordee","family":"Meesing","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand"},{"name":"Research and Diagnostic Center for Emerging Infectious Diseases (RCEID), Khon Kaen University, Khon Kaen, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ploenchan","family":"Chetchotisakd","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"bibr1-09564624221137972","volume-title":"Global health sector strategy on HIV for 2016\u20132021","author":"World Health Organization","year":"2021"},{"key":"bibr2-09564624221137972","volume-title":"Number of PLHIV currently on ART come from health care","author":"Department of Disease Control of Thailand","year":"2020"},{"key":"bibr3-09564624221137972","volume-title":"Thailand national guidelines on HIV\/AIDS treatment and prevention","author":"Thai AIDS Society, Department of Disease Control of Thailand","year":"2017"},{"key":"bibr4-09564624221137972","volume-title":"Thailand national guidelines on HIV\/AIDS diagnosis, treatment and prevention 2020\/2021","author":"Thai AIDS Society, Department of Disease Control of Thailand","year":"2021"},{"key":"bibr5-09564624221137972","volume-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV 2022","author":"Department of health and human service USA","year":"2022"},{"key":"bibr6-09564624221137972","volume-title":"European AIDS clinical society guidelines","author":"European AIDS Clinical Society","year":"2021"},{"key":"bibr7-09564624221137972","volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing hiv infection: recommendations for a public health approach","author":"World Health Organization","year":"2021"},{"key":"bibr8-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"bibr9-09564624221137972","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.72.12.1113"},{"key":"bibr10-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31821d33a5"},{"key":"bibr11-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041811"},{"key":"bibr12-09564624221137972","first-page":"60","volume":"49","author":"So-Ngern A","year":"2018","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"bibr13-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1007\/BF02560501"},{"key":"bibr14-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62041-9"},{"key":"bibr15-09564624221137972","first-page":"56","volume":"17","author":"Libre JM","year":"2015","journal-title":"AIDS Rev"},{"key":"bibr16-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001675"},{"key":"bibr17-09564624221137972","volume-title":"Common terminology criteria for adverse events (CTCAE) version 5.0, Ctep","author":"US Department of Health and Human Services","year":"2017"},{"key":"bibr18-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1161\/circ.106.25.3143"},{"key":"bibr19-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw053"},{"key":"bibr20-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61853-4"},{"key":"bibr21-09564624221137972","first-page":"4","volume-title":"HIV Drug Therapy","author":"Waters L","year":"2018"},{"key":"bibr22-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902824"},{"key":"bibr23-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904340"},{"key":"bibr24-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000616"},{"key":"bibr25-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz999"},{"key":"bibr26-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa195"},{"key":"bibr27-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab537"},{"key":"bibr28-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa177"},{"key":"bibr29-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky507"},{"key":"bibr30-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa40431"},{"key":"bibr31-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19801-x"},{"key":"bibr32-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2020.02.018"},{"key":"bibr33-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw064"},{"key":"bibr34-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2018.1455366"},{"key":"bibr35-09564624221137972","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00027-2"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624221137972","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09564624221137972","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624221137972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:43:59Z","timestamp":1777675439000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09564624221137972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1177\/09564624221137972"],"URL":"https:\/\/doi.org\/10.1177\/09564624221137972","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]}}}